Literature DB >> 17119983

Peritoneal instillation of taurolidine or polihexanide modulates intestinal microcirculation in experimental endotoxemia.

Helge Frieling1, Kai-Steffen Lauer, Matthias Gründling, Taras Usichenko, Konrad Meissner, Theoni Kanellopoulou, Christian Lehmann, Michael Wendt, Dragan Pavlovic.   

Abstract

BACKGROUND AND AIMS: Treatment of peritonitis may include peritoneal lavage/instillation with anti-infective agents like taurolidine or chlorhexidine.
MATERIALS AND METHODS: We examined the effects of peritoneal instillation (INST, 5-ml solution) with taurolidine (TAURO) or polihexanide (POLI-LS) on intestinal microcirculation using intravital microscopy (IVM) in experimental endotoxemia (15 mg/kg lipopolysaccharide i.v.; LPS) in the rat (n = 8 each group), their direct effects on local small blood vessels, aortal rings, and myocardial strips in vitro, as well as plasma interleukin levels.
RESULTS: It was found that LPS produced hypotension (98.8 +/- 9.5 vs 130.4 +/- 10.5 mmHg; mean arterial pressure [MAP], mean +/- standard deviation [SD]), which was further pronounced after INST of TAURO (78.8 +/- 10.8; P < 0.005) or POLI-LS (78.1 +/- 6.0; P < 0.001). IVM revealed a reduction in temporary adhering leucocytes and an increase in firmly adhering leucocytes after INST with TAURO and POLI-LS. Both agents reduced functional capillary density either in the mucosa (POLI-LS vs sham: 259.7 +/- 54 cm/cm(2) vs 337.1 +/- 35.5) or longitudinal muscular layer in LPS rats (TAURO vs sham: 119.8 +/- 14.8 vs 153.7 +/- 11.0). POLI-LS induced local vasodilatation, whereas TAURO induced small vasoconstriction; in vitro, both agents showed vasodilating properties and did not have any effect on myocardial strip contraction.
CONCLUSION: Some of the observed microcirculatory changes could be a result of the direct vascular effects of these agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17119983     DOI: 10.1007/s00384-006-0239-x

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.796


  41 in total

Review 1.  Definition of sepsis.

Authors:  I Matot; C L Sprung
Journal:  Intensive Care Med       Date:  2001       Impact factor: 17.440

2.  Characterization and prevention of phototoxic effects in intravital fluorescence microscopy in the hamster dorsal skinfold model.

Authors:  M Steinbauer; A G Harris; C Abels; K Messmer
Journal:  Langenbecks Arch Surg       Date:  2000-07       Impact factor: 3.445

3.  High doses of taurolidine inhibit advanced intraperitoneal tumor growth in rats.

Authors:  Chris Braumann; Benedikt Stuhldreier; Eva Bobrich; Charalambos Menenakos; Stephan Rogalla; Christoph A Jacobi
Journal:  J Surg Res       Date:  2005-11       Impact factor: 2.192

Review 4.  [Therapy of peritonitis today. Surgical management and adjuvant therapy strategies].

Authors:  H B Reith
Journal:  Langenbecks Arch Chir       Date:  1997

Review 5.  Management of abdominal sepsis.

Authors:  D Berger; K Buttenschoen
Journal:  Langenbecks Arch Surg       Date:  1998-03       Impact factor: 3.445

6.  Microvascular vasoconstriction and mucosal hypoperfusion of the rat small intestine during bacteremia.

Authors:  C J Theuer; M A Wilson; G D Steeb; R N Garrison
Journal:  Circ Shock       Date:  1993-05

7.  Taurolidine peritoneal lavage as prophylaxis against infection after elective colorectal surgery.

Authors:  D M Baker; J A Jones; J S Nguyen-Van-Tam; J H Lloyd; D L Morris; J B Bourke; R J Steele; J D Hardcastle
Journal:  Br J Surg       Date:  1994-07       Impact factor: 6.939

8.  Selective gut microcirculatory control (SGMC) in septic rats: a novel approach with a locally applied vasoactive drug.

Authors:  M Hersch; W S Madorin; W J Sibbald; C M Martin
Journal:  Shock       Date:  1998-10       Impact factor: 3.454

9.  In-vitro antibacterial activity of noxythiolin and taurolidine.

Authors:  J I Blenkharn
Journal:  J Pharm Pharmacol       Date:  1990-08       Impact factor: 3.765

10.  Treatment of glioblastoma with intravenous taurolidine. First clinical experience.

Authors:  Ruediger Stendel; Thomas Picht; Andreas Schilling; Jens Heidenreich; Christoph Loddenkemper; Werner Jänisch; Mario Brock
Journal:  Anticancer Res       Date:  2004 Mar-Apr       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.